Cytek Biosciences (CTKB)
Market Price (5/30/2026): $4.19 | Market Cap: $539.3 MilSector: Health Care | Industry: Health Care Equipment
Cytek Biosciences (CTKB)
Market Price (5/30/2026): $4.19Market Cap: $539.3 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -130% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -44 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.3% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% Key risksCTKB key risks include [1] weak demand from its key academic and government sectors, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -130% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -44 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.3% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% |
| Key risksCTKB key risks include [1] weak demand from its key academic and government sectors, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Cytek Biosciences (CTKB) stock has lost about 15% since 1/31/2026 because of the following key factors:
1. Cytek Biosciences missed Q1 2026 earnings expectations and reported wider net losses.
The company announced a diluted EPS of -$0.15 for the first quarter of 2026, significantly missing analysts' consensus estimate of -$0.09 by 66.67%. Furthermore, the net loss for the quarter expanded to $18.9 million, compared to a net loss of $11.4 million in the first quarter of 2025. This negative earnings surprise directly contributed to a 6.3% decline in the stock price on May 7, 2026, the day the financial results were reported.
2. Increased operating expenses, particularly in general and administrative costs, pressured profitability.
During Q1 2026, Cytek Biosciences' operating expenses rose by 13% year-over-year, reaching $39.7 million. A substantial portion of this increase stemmed from a 43% jump in General and Administrative (G&A) expenses compared to Q1 2025. These elevated G&A costs were primarily driven by litigation-related and outside consulting expenses, as well as bad debt reserves, which contributed to the company's widening net loss.
Show more
Stock Movement Drivers
Fundamental Drivers
The -16.2% change in CTKB stock from 1/31/2026 to 5/29/2026 was primarily driven by a -18.5% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.00 | 4.19 | -16.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 197 | 204 | 3.7% |
| P/S Multiple | 3.2 | 2.6 | -18.5% |
| Shares Outstanding (Mil) | 128 | 129 | -0.9% |
| Cumulative Contribution | -16.2% |
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| CTKB | -16.2% | |
| Market (SPY) | 9.6% | 28.4% |
| Sector (XLV) | -3.0% | 22.9% |
Fundamental Drivers
The 7.4% change in CTKB stock from 10/31/2025 to 5/29/2026 was primarily driven by a 4.6% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.90 | 4.19 | 7.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 196 | 204 | 4.2% |
| P/S Multiple | 2.5 | 2.6 | 4.6% |
| Shares Outstanding (Mil) | 127 | 129 | -1.4% |
| Cumulative Contribution | 7.4% |
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| CTKB | 7.4% | |
| Market (SPY) | 11.5% | 22.7% |
| Sector (XLV) | 4.5% | 24.6% |
Fundamental Drivers
The 12.9% change in CTKB stock from 4/30/2025 to 5/29/2026 was primarily driven by a 10.6% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.71 | 4.19 | 12.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 200 | 204 | 1.9% |
| P/S Multiple | 2.4 | 2.6 | 10.6% |
| Shares Outstanding (Mil) | 129 | 129 | 0.3% |
| Cumulative Contribution | 12.9% |
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| CTKB | 12.9% | |
| Market (SPY) | 38.0% | 29.7% |
| Sector (XLV) | 8.3% | 31.7% |
Fundamental Drivers
The -63.5% change in CTKB stock from 4/30/2023 to 5/29/2026 was primarily driven by a -72.0% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.48 | 4.19 | -63.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 164 | 204 | 24.5% |
| P/S Multiple | 9.4 | 2.6 | -72.0% |
| Shares Outstanding (Mil) | 135 | 129 | 4.9% |
| Cumulative Contribution | -63.5% |
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| CTKB | -63.5% | |
| Market (SPY) | 89.0% | 30.3% |
| Sector (XLV) | 17.7% | 29.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CTKB Return | -13% | -37% | -11% | -29% | -22% | -18% | -78% |
| Peers Return | 32% | -16% | -7% | -2% | -1% | -7% | -7% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| CTKB Win Rate | 50% | 42% | 50% | 25% | 42% | 20% | |
| Peers Win Rate | 70% | 43% | 52% | 45% | 53% | 36% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| CTKB Max Drawdown | - | -57% | -70% | -49% | -67% | -42% | |
| Peers Max Drawdown | -15% | -32% | -31% | -19% | -35% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BDX, TMO, DHR, A, BIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
| Event | CTKB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -54.9% | -18.8% |
| % Gain to Breakeven | 121.5% | 23.1% |
| Time to Breakeven | 175 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.5% | -9.5% |
| % Gain to Breakeven | 124.6% | 10.5% |
| Time to Breakeven | 49 days | 24 days |
In The Past
Cytek Biosciences's stock fell -54.9% during the 2025 US Tariff Shock. Such a loss loss requires a 121.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CTKB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -54.9% | -18.8% |
| % Gain to Breakeven | 121.5% | 23.1% |
| Time to Breakeven | 175 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.5% | -9.5% |
| % Gain to Breakeven | 124.6% | 10.5% |
| Time to Breakeven | 49 days | 24 days |
In The Past
Cytek Biosciences's stock fell -54.9% during the 2025 US Tariff Shock. Such a loss loss requires a 121.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cytek Biosciences (CTKB)
AI Analysis | Feedback
1. Illumina for cell analysis.
2. A specialized Thermo Fisher Scientific for advanced cell profiling.
AI Analysis | Feedback
- Aurora and Northern Lights systems: Spectrum flow cytometers that deliver cell analysis by utilizing fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
- Aurora Cell Sorter system: A system leveraging full spectrum profiling technology to broaden potential applications across cell analysis through cell sorting.
- Reagents and Kits: Includes cFluor reagents (fluorochrome conjugated antibodies for cell identification) and a 25-color immunoprofiling assay (a turnkey solution for identifying major human immune subpopulations).
- Automated Micro-sampling and Sample Loader systems: Automated plate loaders designed to integrate seamlessly into their Aurora and Northern Lights systems for efficient sample handling.
- SpectroFlo software: Intuitive software providing workflow solutions from quality control to data analysis for their Aurora and Northern Lights systems.
- Customer Support Tools: Resources and services provided to assist customers with their products and ensure optimal performance.
AI Analysis | Feedback
Cytek Biosciences (symbol: CTKB) primarily sells its products and services to institutional clients, rather than individuals. Based on the provided background information, its major customers fall into the following categories:- Pharmaceutical and biopharma companies
- Academic research centers
- Clinical research organizations
AI Analysis | Feedback
nullAI Analysis | Feedback
Wenbin Jiang, Ph.D. Chief Executive Officer and Chairman of the Board
Dr. Wenbin Jiang is a co-founder of Cytek Biosciences and has served as its Chief Executive Officer and a member of the Board since December 2014. Prior to Cytek, Dr. Jiang co-founded E2O Communications, Inc., a fiber optic subsystems manufacturing company, in 1998. E2O Communications was subsequently acquired by JDS Uniphase Corporation in 2004. He is also an accomplished inventor, holding over 95 U.S. patents and authoring numerous technical papers and book chapters.
William McCombe Chief Financial Officer
William McCombe was appointed Chief Financial Officer of Cytek Biosciences in March 2024. He brings extensive experience as a public company CFO, having held the position at Velo3D, HZO, and serving as EVP and CFO at Maxar Technologies. Mr. McCombe also has a significant background in investment banking, with over 20 years of experience, including roles as a Managing Director at Morgan Stanley and Bank of America.
Ming Yan, Ph.D. Chief Technology Officer
Dr. Ming Yan is a co-founder of Cytek Biosciences and has served as its Chief Technology Officer and a member of the Board since 2015. He possesses over 20 years of experience in research and development, with previous roles at AT&T Bell Laboratories, Lawrence Livermore National Labs, and BD Biosciences.
Valerie Barnett Chief Legal Officer and Corporate Secretary
Valerie Barnett serves as the Chief Legal Officer and Corporate Secretary for Cytek Biosciences.
Philippe Busque, Ph.D. Senior Vice President, Global Sales & Services
Dr. Philippe Busque holds the position of Senior Vice President of Global Sales & Services at Cytek Biosciences.
AI Analysis | Feedback
Key Risks to Cytek Biosciences (CTKB)
Cytek Biosciences, Inc. (CTKB) faces several key risks that could impact its business operations and financial performance. These risks are primarily related to external market conditions, internal operational efficiencies, and supply chain vulnerabilities.
- Challenging Capital Equipment Spending and Funding Uncertainties: A significant risk for Cytek Biosciences is the "softness" in capital equipment spending, particularly within the academic and government sectors, especially in the United States. This is directly linked to funding uncertainties, such as those related to National Institutes of Health (NIH) funding policies. This market condition has directly contributed to declines in instrument sales in certain regions and acts as a major headwind for the company, offsetting gains in other areas. Customer demand is pressured by these external factors, leading to reduced instrument sales in academic and government segments.
- Operational Efficiency Challenges and Pressure on Profitability: Cytek Biosciences has experienced considerable pressure on its profitability and operational efficiency. The company's gross margin has been under strain, with reports of a decline, and it has shifted from reporting net income to net losses in recent periods. This margin compression is attributed to factors such as higher materials and tariff costs, increased headcount, and elevated operating expenses, including litigation-related costs. These challenges indicate difficulties in translating revenue growth into sustainable profits and efficient cash flow generation.
- Dependence on Sole and Single-Source Suppliers: Cytek Biosciences relies on a limited number of, and in some cases, sole or single-source suppliers for critical components of its instruments, such as certain lasers and semiconductors. These specialized parts are fundamental to the optical, electrical, and fluidic subassemblies of their core products. This dependency exposes the company to risks of increased input costs, potential supply shortages, and significant lead times required to identify and qualify alternative suppliers should a single-source provider fail or experience disruptions.
AI Analysis | Feedback
null
AI Analysis | Feedback
Cytek Biosciences (CTKB) operates in the cell analysis solutions market, with its main products encompassing flow cytometry instruments, reagents, and associated software and automated systems. The company's addressable markets can be primarily segmented into the broader cell analysis market, and more specifically, the flow cytometry instruments and flow cytometry reagents markets.
The global cell analysis market was estimated at approximately $34.3 billion in 2025 and is projected to reach $81.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2033. Another estimate places the global cell analysis market size at $39.22 billion in 2026, with a projection to reach $93.23 billion by 2034, exhibiting a CAGR of 11.43% during 2026–2034. North America held the largest share of the global cell analysis market, accounting for 40.0% in 2025. The Asia-Pacific region is anticipated to be the fastest-growing market, with a CAGR of 13.1% from 2026 to 2033.
For the more specific flow cytometry market, which is central to Cytek's offerings, the global market size was approximately $6.13 billion in 2025, growing to $6.59 billion in 2026, and is expected to reach around $12.97 billion by 2035, at a CAGR of 7.78% from 2026 to 2035. Other estimates for the global flow cytometry market include a projection to reach $9.85 billion by 2033 from $5.06 billion in 2025, with a CAGR of 8.7% from 2025 to 2033. Additionally, the global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a CAGR of 8.2% from 2024 to 2029. North America held the largest share of the flow cytometry market, at 39.76% in 2025 and 41.9% in 2024. The Asia-Pacific region is also a significant growth area, projected to achieve a CAGR of 8.35% from 2026 to 2035.
Within the flow cytometry market, the instruments segment is a key component of Cytek's business. The global flow cytometry instrument market size is projected to be approximately $4.44 billion in 2026 and is expected to reach about $9.59 billion by 2035, growing at a CAGR of 8.8%. North America accounts for approximately 42% of the global flow cytometry instrument market share, while Europe holds about 29% and Asia-Pacific contributes 22% of global installations.
The market for flow cytometer reagents, including Cytek's cFluor reagents, was estimated at approximately $3.33 billion in 2024. This market is projected to grow from $3.64 billion in 2025 to $8.77 billion by 2035, with a CAGR of 9.2% during this period. North America is a leader in the flow cytometer reagents market, holding approximately $1.67 billion in 2024. The Asia-Pacific region's reagents market was valued at approximately $0.55 billion in 2024 and is experiencing rapid growth. In 2024, reagents and consumables collectively accounted for the largest share, 54.0%, of the flow cytometry market. Cytek estimates an annual addressable market of $150 million for non-Cytek reagents currently used in its more than 3,000 installed instruments.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Cytek Biosciences (CTKB) over the next 2-3 years:
- Growth in Recurring Revenue from Services and Reagents: Cytek Biosciences anticipates continued strong growth in its recurring revenue streams, particularly from services and reagents. This growth is directly tied to an expanding global installed base of Cytek instruments, which reached 2,247 instruments in Q1 2024 and 3,456 units as of September 30, 2025. As more instruments are placed, the demand for associated services and cFluor reagents, which are used to identify cells of interest for analysis on its instruments, increases. Management expects recurring revenue as a share of total revenue to continue growing.
- New Product Launches and Product Innovation: The introduction of innovative new products, such as the Cytek Aurora Evo system and the Muse Micro System, is expected to drive future revenue growth. The Aurora Evo system, for instance, has already contributed to significant unit growth in the combined Aurora category. Cytek also leverages its full spectrum profiling technology and aims to maintain leadership in instruments.
- Geographic Expansion and Market Recovery: Cytek Biosciences is experiencing and expects continued momentum from its global expansion efforts and market recoveries in key regions. Strong demand and double-digit growth in instrument sales and overall revenue have been observed in the Asia-Pacific (APAC) region, including China. Additionally, the company has noted a rebound and improved market environment in the Europe, Middle East, and Africa (EMEA) region and stabilization in the U.S. market, particularly among academic and government customers.
- Expansion into Clinical Applications and the Clinical Business: Cytek is strategically expanding its clinical business, especially in Europe and APAC, by pursuing regulatory clearances for its products, such as 510(k) and IVDR clearances. This focus aims to move its Full Spectrum Profiling technology into routine clinical applications, such as leukemia and lymphoma monitoring, thereby accessing a significant portion of the flow cytometry market. The company has already received China National Medical Products Association (NMPA) approval for a single-laser 6-color TBNK panel and registered 18 single-color reagents for IVD use in China for clinical applications.
AI Analysis | Feedback
Share Repurchases
- In June 2024, Cytek Biosciences announced that its Board of Directors approved a stock repurchase program authorizing the buyback of up to $50 million of its common stock, slated to run through December 31, 2024.
- In December 2024, the company's Board of Directors approved a new stock repurchase program for up to an additional $50 million of common stock, authorized to commence on January 1, 2025, and remain in effect until December 31, 2025.
- During 2025, Cytek repurchased approximately 3.3 million shares for $15.1 million.
Share Issuance
- Cytek Biosciences completed its initial public offering (IPO) in July 2021, issuing 11,764,706 shares of its common stock at $17.00 per share.
- The IPO generated gross proceeds of $200 million for Cytek Biosciences from its share sales.
Capital Expenditures
- Capital expenditures for 2025 amounted to $4.1 million.
- Cytek established a new manufacturing facility in Singapore, which commenced operations in Q1 2025 and began generating revenue, aiming to access low-cost manufacturing, increase capacity, and enhance global supply flexibility.
- The company continues to invest in commercial capabilities, including its sales infrastructure and reagent sales force, to drive future revenue growth and market penetration.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Cytek Biosciences Earnings Notes | 12/16/2025 | |
| Cytek Biosciences Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 | |
| Now Is Not The Time To Buy Cytek Biosciences Stock | 05/16/2025 | |
| Cytek Biosciences (CTKB) Valuation Ratios Comparison | 05/15/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CTKB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02282022 | CTKB | Cytek Biosciences | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -14.7% | -24.5% | -45.7% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 164.89 |
| Mkt Cap | 39.8 |
| Rev LTM | 14,216 |
| Op Inc LTM | 2,274 |
| FCF LTM | 2,025 |
| FCF 3Y Avg | 2,107 |
| CFO LTM | 2,614 |
| CFO 3Y Avg | 2,657 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 0.9% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | -1.5% |
| Op Inc Chg 3Y Avg | -7.0% |
| Op Mgn LTM | 16.3% |
| Op Mgn 3Y Avg | 15.5% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 19.0% |
| CFO/Rev 3Y Avg | 18.6% |
| FCF/Rev LTM | 14.2% |
| FCF/Rev 3Y Avg | 15.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 39.8 |
| P/S | 3.7 |
| P/Op Inc | 24.3 |
| P/EBIT | 22.7 |
| P/E | 32.4 |
| P/CFO | 18.3 |
| Total Yield | 3.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.9% |
| 3M Rtn | -5.9% |
| 6M Rtn | -13.9% |
| 12M Rtn | 21.5% |
| 3Y Rtn | -12.5% |
| 1M Excs Rtn | -2.3% |
| 3M Excs Rtn | -16.1% |
| 6M Excs Rtn | -27.5% |
| 12M Excs Rtn | -5.6% |
| 3Y Excs Rtn | -96.6% |
Price Behavior
| Market Price | $4.19 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 07/23/2021 | |
| Distance from 52W High | -28.7% | |
| 50 Days | 200 Days | |
| DMA Price | $4.37 | $4.48 |
| DMA Trend | up | down |
| Distance from DMA | -4.1% | -6.5% |
| 3M | 1YR | |
| Volatility | 53.9% | 61.9% |
| Downside Capture | 124.68 | 118.17 |
| Upside Capture | 53.69 | 139.14 |
| Correlation (SPY) | 22.7% | 28.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.92 | 1.16 | 1.29 | 1.28 | 1.69 | 1.35 |
| Up Beta | 0.27 | 0.47 | 0.31 | 1.01 | 1.70 | 1.32 |
| Down Beta | -2.76 | 0.52 | 1.56 | 1.41 | 1.50 | 0.97 |
| Up Capture | 102% | 146% | 129% | 158% | 220% | 167% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 14 | 22 | 30 | 59 | 123 | 359 |
| Down Capture | 750% | 178% | 188% | 125% | 156% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 7 | 20 | 32 | 64 | 125 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTKB | |
|---|---|---|---|---|
| CTKB | 79.1% | 61.8% | 1.18 | - |
| Sector ETF (XLV) | 15.8% | 14.6% | 0.78 | 27.4% |
| Equity (SPY) | 30.3% | 11.8% | 1.94 | 27.4% |
| Gold (GLD) | 37.5% | 26.7% | 1.17 | 1.4% |
| Commodities (DBC) | 39.6% | 18.8% | 1.63 | -18.6% |
| Real Estate (VNQ) | 12.5% | 13.1% | 0.64 | 22.0% |
| Bitcoin (BTCUSD) | -31.8% | 41.6% | -0.81 | 13.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTKB | |
|---|---|---|---|---|
| CTKB | -25.0% | 65.7% | -0.18 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 31.5% |
| Equity (SPY) | 14.3% | 17.0% | 0.66 | 36.6% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 4.2% |
| Commodities (DBC) | 10.2% | 19.4% | 0.41 | 2.9% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 29.7% |
| Bitcoin (BTCUSD) | 14.6% | 54.6% | 0.46 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTKB | |
|---|---|---|---|---|
| CTKB | -13.4% | 65.7% | -0.18 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 31.5% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 36.6% |
| Gold (GLD) | 13.3% | 16.0% | 0.69 | 4.2% |
| Commodities (DBC) | 7.3% | 17.9% | 0.33 | 2.9% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 29.7% |
| Bitcoin (BTCUSD) | 67.0% | 66.9% | 1.06 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated N/A/N/A/N/A| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -6.3% | -31.8% | |
| 2/26/2026 | 1.8% | -0.5% | -1.8% |
| 11/5/2025 | 13.2% | 20.0% | 21.2% |
| 8/6/2025 | 5.7% | 7.2% | 3.3% |
| 5/8/2025 | -22.8% | -29.3% | -6.1% |
| 2/27/2025 | -6.7% | -7.3% | -16.8% |
| 11/5/2024 | 36.0% | 29.4% | 20.2% |
| 8/6/2024 | -9.4% | -4.8% | -3.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 8 | 5 |
| # Negative | 12 | 13 | 15 |
| Median Positive | 5.7% | 11.0% | 21.2% |
| Median Negative | -5.7% | -7.3% | -13.0% |
| Max Positive | 36.0% | 30.2% | 53.2% |
| Max Negative | -24.0% | -41.0% | -31.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
Recent Forward Guidance
Updated 5/28/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 205.00 Mil | 208.50 Mil | 212.00 Mil | 0 | Affirmed | Guidance: 208.50 Mil for 2026 | |
| 2026 Revenue Growth | 2.0% | 3.5% | 5.0% | 0 | 0 | Affirmed | Guidance: 3.5% for 2026 |
Prior: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 205.00 Mil | 208.50 Mil | 212.00 Mil | 4.0% | Higher New | Actual: 200.50 Mil for 2025 | |
| 2026 Revenue Growth | 2.0% | 3.5% | 5.0% | 3.5% | Higher New | Actual: 0.0% for 2025 | |
Insider Activity
Updated 5/20/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | McCombe, William D | Chief Financial Officer | Direct | Buy | 6032025 | 2.78 | 35,000 | 97,300 | 154,974 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.